Business Wire

Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective Disorder

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the past, today announced it has dosed the first participant ...
Business Wire

Lyndra Therapeutics Announces Positive Data from Pivotal Phase 3 Study with Oral Weekly Risperidone (LYN-005) for Schizophrenia

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics ®, a clinical-stage biopharmaceutical company, today announced positive data from the STARLYNG-1 (LYN-005-C-301) study, comparing the ...
EurekAlert!

Risperdal® (risperidone) produces continuous improvement of 'manic' symptoms in bipolar disorder

21 September 2003 – Prague – When used alone, RISPERDAL® (risperidone) significantly improves symptoms of acute mania in persons with bipolar disorder as early as one week after treatment begins, ...
Healio

Extended-release risperidone capsule may improve drug adherence in schizophrenia

Please provide your email address to receive an email when new articles are posted on . An oral, ultra-long-acting, extended-release risperidone capsule provided sustained therapeutic levels of ...